Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade C 36.24 -0.25% -0.09
URGN closed down 0.25 percent on Wednesday, September 18, 2019, on 85 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical URGN trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Reached Overbought Strength -0.25%
Upper Bollinger Band Walk Strength -0.25%
Overbought Stochastic Strength -0.25%
Up 3 Days in a Row Strength -0.25%
Upper Bollinger Band Touch Strength -0.25%
Upper Bollinger Band Walk Strength 0.67%
Above Upper BB Strength 0.67%
Upper Bollinger Band Touch Strength 0.67%

Older signals for URGN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Medicine Biopharmaceutical Cancer Surgery Chemotherapy Antineoplastic Drugs Overactive Bladder Non Muscle Invasive Bladder Cancer Interstitial Cystitis
Is URGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 55.49
52 Week Low 30.48
Average Volume 183,905
200-Day Moving Average 38.1928
50-Day Moving Average 32.9036
20-Day Moving Average 33.3125
10-Day Moving Average 34.651
Average True Range 1.5925
ADX 31.69
+DI 30.9366
-DI 9.4854
Chandelier Exit (Long, 3 ATRs ) 32.2975
Chandelier Exit (Short, 3 ATRs ) 35.3575
Upper Bollinger Band 36.8135
Lower Bollinger Band 29.8115
Percent B (%b) 0.92
BandWidth 21.019137
MACD Line 0.8688
MACD Signal Line 0.455
MACD Histogram 0.4137
Fundamentals Value
Market Cap 471.45 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -21.70
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.06
Resistance 3 (R3) 37.94 37.21 37.75
Resistance 2 (R2) 37.21 36.75 37.27 37.65
Resistance 1 (R1) 36.73 36.47 36.37 36.85 37.55
Pivot Point 36.00 36.00 35.82 36.06 36.00
Support 1 (S1) 35.52 35.54 35.16 35.64 34.93
Support 2 (S2) 34.79 35.26 34.85 34.83
Support 3 (S3) 34.31 34.79 34.73
Support 4 (S4) 34.43